

# Daniel J. Mller

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9564561/daniel-j-muller-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260  
papers

9,532  
citations

51  
h-index

86  
g-index

282  
ext. papers

11,263  
ext. citations

5.1  
avg, IF

6.07  
L-index

#	Paper	IF	Citations
260	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 816465	5	
259	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 101	8.6	3
258	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2022</b> , 12, 204512532210965	4.9	1
257	The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. <i>European Journal of Nutrition</i> , <b>2021</b> , 60, 2905-2921	5.2	8
256	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. <i>Drug Development Research</i> , <b>2021</b> , 82, 678-684	5.1	3
255	Older molecular brain age in severe mental illness. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 3646-3656	15.1	8
254	Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	2
253	Encountering Pharmacogenetic Test Results in the Psychiatric Clinic. <i>Canadian Journal of Psychiatry</i> , <b>2021</b> , 7067437211058847	4.8	0
252	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , <b>2021</b> , 32, 102864	5.3	1
251	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. <i>Psychological Medicine</i> , <b>2021</b> , 51, 2742-2751	6.9	3
250	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 5-17	2	40
249	Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 81-89	2	3
248	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 111, 110194	5.5	4
247	The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	7
246	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , <b>2021</b> , 35, 291-304	6.7	0
245	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 225-231	2	1
244	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , <b>2021</b> , 35, 439-450	6.7	1

243	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253023	3.7	1
242	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 31-39	4.6	3
241	Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1305, 231-255	3.6	1
240	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 127	8.6	5
239	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 617997	5	3
238	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 888-896	6.1	55
237	Economic evaluation in psychiatric pharmacogenomics: a systematic review. <i>Pharmacogenomics Journal</i> , <b>2021</b> , 21, 533-541	3.5	5
236	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. <i>Human Brain Mapping</i> , <b>2021</b> , 42, 4940-4957	5.9	3
235	A systematic review on neuromodulation therapies for reducing body weight in patients with obesity. <i>Obesity Reviews</i> , <b>2021</b> , 22, e13309	10.6	3
234	Changes in RNA expression levels during antidepressant treatment: a systematic review. <i>Journal of Neural Transmission</i> , <b>2021</b> , 128, 1461-1477	4.3	0
233	Pharmacogenetics-Guided Advances in Antipsychotic Treatment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 582-588	6.1	4
232	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 439	8.6	1
231	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , <b>2021</b> ,	5.1	1
230	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 469	8.6	
229	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e31439	3.9	2
228	Reviewing pharmacogenetics to advance precision medicine for opioids. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 142, 112060	7.5	2
227	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , <b>2021</b> , 132, 105348	5	0
226	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11

225	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénomiques pertinents en psychiatrie au Canada. <i>Canadian Journal of Psychiatry</i> , <b>2020</b> , 65, 521-530	4.8	15
224	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 100, 109867	5.5	4
223	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. <i>American Journal of Geriatric Psychiatry</i> , <b>2020</b> , 28, 609-629	6.5	8
222	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 102, 109952	5.5	5
221	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , <b>2020</b> , 17, 30-40	1	3
220	Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. <i>Current Topics in Medicinal Chemistry</i> , <b>2020</b> , 20, 1398-1414	3	1
219	Opportunities and challenges of implementation models of pharmacogenomics in clinical practice <b>2020</b> , 449-457		
218	Genetic testing in psychiatry: State of the evidence <b>2020</b> , 437-448		
217	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 921-932	5.1	8
216	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 68-85	5.8	5
215	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , <b>2020</b> , 264, 414-424	6.6	3
214	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , <b>2020</b> , 41, 1400-1415	5.9	5
213	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 575540	5.6	23
212	Liver enzyme gene and tardive dyskinesia. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 1065-1072	2.6	2
211	Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 37, 39-48	1.2	1
210	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , <b>2020</b> , 8, 391	6	
209	Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review: Études Pharmacogénomiques en Déficiences Intellectuelles et Trouble du Spectre de L'Autisme: Une Revue Systématique. <i>Canadian Journal of Psychiatry</i> , <b>2020</b> , 706743720971950	4.8	1
208	Genome-Wide Association Study of Sleep Disturbances in Depressive Disorders. <i>Molecular Neuropsychiatry</i> , <b>2020</b> , 5, 34-43	4.9	1

207	Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. <i>Molecular Neuropsychiatry</i> , <b>2020</b> , 5, 1-26	4.9	17
206	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. <i>Neuropsychobiology</i> , <b>2020</b> , 79, 5-12	4	7
205	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , <b>2020</b> , 50, 2536-2547	6.9	6
204	From the Origins of Pharmacogenetics to First Applications in Psychiatry. <i>Pharmacopsychiatry</i> , <b>2020</b> , 53, 155-161	2	8
203	Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 119, 33-47	5.2	8
202	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. <i>Schizophrenia Research</i> , <b>2019</b> , 212, 204-212	3.6	5
201	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 94, 109659	5.5	6
200	Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 309-312	6.1	28
199	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 114, 67-74	5.2	0
198	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , <b>2019</b> , 257, 765-773	6.6	13
197	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 254	8.6	18
196	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , <b>2019</b> , 44, 223-236	4.5	22
195	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	38
194	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	10
193	Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1339	5.6	7
192	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , <b>2019</b> , 49, 1629-1638	6.9	14
191	Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature. <i>Journal of Neural Transmission</i> , <b>2019</b> , 126, 65-85	4.3	8
190	Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. <i>Current Opinion in Psychiatry</i> , <b>2019</b> , 32, 7-15	4.9	77

189	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. <i>Journal of Neural Transmission</i> , <b>2019</b> , 126, 27-33	4.3	8
188	Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. <i>Psychiatry Research</i> , <b>2019</b> , 279, 111-115	9.9	19
187	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , <b>2019</b> , 20, 91-95	3.8	8
186	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 99, 62-68	5.2	36
185	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 574-581	6.1	139
184	Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 96, 265-272	5.2	21
183	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , <b>2018</b> , 19, S97-S105	3.8	9
182	The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2018</b> , 268, 3-15	5.1	47
181	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 406-412	3.5	14
180	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , <b>2018</b> , 686, 17-22	3.3	6
179	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , <b>2018</b> , 227, 542-549	6.6	46
178	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1269-1284	2.6	8
177	Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 974	5.6	12
176	PharmGKB summary: clozapine pathway, pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , <b>2018</b> , 28, 214-222	1.9	22
175	Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 1090	14.5	3
174	Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. <i>Human Psychopharmacology</i> , <b>2018</b> , 33, e2659	2.3	6
173	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 468-475	11.9	29
172	Association study between the neurexin-1 gene and tardive dyskinesia. <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2568	2.3	6



171	Cognitive and psychosocial function in retired professional hockey players. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 512-519	5.5	36
170	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , <b>2017</b> , 8, 15497	17.4	93
169	Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 37-44	6.1	269
168	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 1-6	1.9	8
167	Verbal memory improvement in first-episode psychosis - $\Delta$ carriers: a pleiotropic effect?. <i>Neuropsychiatric Disease and Treatment</i> , <b>2017</b> , 13, 2945-2953	3.1	5
166	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , <b>2017</b> , 2, 185-197	4.9	10
165	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , <b>2017</b> , 11, 741	5.1	53
164	C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 79, 442-451	5.5	15
163	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. <i>Schizophrenia Research</i> , <b>2017</b> , 187, 67-73	3.6	13
162	Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. <i>Molecular Neuropsychiatry</i> , <b>2016</b> , 2, 1-14	4.9	42
161	Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. <i>Neuropsychobiology</i> , <b>2016</b> , 74, 169-175	4	4
160	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 121-34	2.3	15
159	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 105	4.2	80
158	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2016</b> , 19,	5.8	43
157	Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 103-9	2.6	28
156	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 221-9	3.8	22
155	Pharmacogenetics of Serious Antipsychotic Side Effects <b>2016</b> , 21-38		
154	Low-Dose Lithium Stabilizes Human Endothelial Barrier by Decreasing MLC Phosphorylation and Universally Augments Cholinergic Vasorelaxation Capacity in a Direct Manner. <i>Frontiers in Physiology</i> , <b>2016</b> , 7, 593	4.6	20

153	The role of the ITIH3 rs2535629 variant in antipsychotic response. <i>Schizophrenia Research</i> , <b>2016</b> , 176, 131-135	3.6	12
152	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 172-85	6.1	100
151	Molecular mechanisms in lithium-associated renal disease: a systematic review. <i>International Urology and Nephrology</i> , <b>2016</b> , 48, 1843-1853	2.3	12
150	Genetics of Common Antipsychotic-Induced Adverse Effects. <i>Molecular Neuropsychiatry</i> , <b>2016</b> , 2, 61-78	4.9	42
149	Childhood Abuse History in Depression Predicts Better Response to Antidepressants with Higher Serotonin Transporter Affinity: A Pilot Investigation. <i>Neuropsychobiology</i> , <b>2016</b> , 74, 78-83	4	11
148	A differential impact of lithium on endothelium-dependent but not on endothelium-independent vessel relaxation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2016</b> , 67, 98-106	5.5	15
147	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 352-6	3.5	27
146	Pharmacogenetics of tardive dyskinesia: an updated review of the literature. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1339-51	2.6	32
145	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. <i>Canadian Journal of Psychiatry</i> , <b>2016</b> , 61, 540-60	4.8	469
144	The role of genetic variation across IL-1 $\beta$ , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , <b>2015</b> , 16, 45-56	3.8	26
143	The Effects of Video Games on Cognition and Brain Structure: Potential Implications for Neuropsychiatric Disorders. <i>Current Psychiatry Reports</i> , <b>2015</b> , 17, 71	9.1	34
142	Neurogenetic variations in norepinephrine availability enhance perceptual vividness. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 6506-16	6.6	80
141	Genetic variation in CYP3A43 is associated with response to antipsychotic medication. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 29-34	4.3	17
140	Association study of GABAA $\alpha$ receptor subunit gene variants in antipsychotic-associated weight gain. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 7-12	1.7	13
139	Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"? <i>Current Psychiatry Reports</i> , <b>2015</b> , 17, 96	9.1	28
138	Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1709-31	5.5	26
137	Genetic variation in IL-1 $\beta$ , IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1919-29	2.6	13
136	Linking unfounded beliefs to genetic dopamine availability. <i>Frontiers in Human Neuroscience</i> , <b>2015</b> , 9, 521	3.3	10



135	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 127-34	6.1	488
134	Physicians' Opinions following pharmacogenetic testing for psychotropic medication. <i>Psychiatry Research</i> , <b>2015</b> , 229, 913-8	9.9	39
133	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 5-22	2.6	13
132	Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , <b>2014</b> , 29, 330-5	2.3	7
131	Deletion variant in the ADRA2B gene increases coupling between emotional responses at encoding and later retrieval of emotional memories. <i>Neurobiology of Learning and Memory</i> , <b>2014</b> , 112, 222-9	3.1	57
130	Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1147-57	2.6	34
129	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 404-10	3.8	15
128	Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. <i>Current Psychiatry Reports</i> , <b>2014</b> , 16, 473	9.1	50
127	Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 251-8	3.8	5
126	Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. <i>Pharmacotherapy</i> , <b>2014</b> , 34, 166-84	5.8	53
125	Depression, antidepressants, and bone health in older adults: a systematic review. <i>Journal of the American Geriatrics Society</i> , <b>2014</b> , 62, 1434-41	5.6	37
124	Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 54, 36-42	5.2	21
123	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , <b>2014</b> , 215, 799-800	9.9	8
122	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. <i>Psychiatry Research</i> , <b>2014</b> , 219, 255-68	9	11
121	Pharmacogenetics of antipsychotics. <i>Canadian Journal of Psychiatry</i> , <b>2014</b> , 59, 76-88	4.8	62
120	Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight. <i>Translational Developmental Psychiatry</i> , <b>2014</b> , 2, 24663		5
119	The uncanny return of the race concept. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 836	3.3	21
118	Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. <i>Current Drug Metabolism</i> , <b>2014</b> , 15, 209-17	3.5	265

117	Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 423-31	2.6	11
116	A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1347-54	8.7	24
115	Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. <i>Molecular Psychiatry</i> , <b>2014</b> , 19, 403-5	15.1	19
114	Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. <i>Current Psychiatry Reports</i> , <b>2014</b> , 16, 510	9.1	46
113	Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. <i>Neuropsychobiology</i> , <b>2014</b> , 69, 59-63	4	14
112	Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 176-81	3.5	49
111	Pharmacogenetics and outcome with antipsychotic drugs. <i>Dialogues in Clinical Neuroscience</i> , <b>2014</b> , 16, 555-66	5.7	51
110	Pharmacogenetics of antipsychotic treatment in schizophrenia. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1175, 557-87	1.4	19
109	Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 324-8	6.1	168
108	Genes for emotion-enhanced remembering are linked to enhanced perceiving. <i>Psychological Science</i> , <b>2013</b> , 24, 2244-53	7.9	110
107	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 1760-5	5.2	47
106	Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 402-8	6.1	334
105	Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. <i>International Review of Psychiatry</i> , <b>2013</b> , 25, 554-71	3.6	50
104	Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. <i>World Journal of Biological Psychiatry</i> , <b>2013</b> , 14, 500-8	3.8	62
103	Analysis of 34 candidate genes in bupropion and placebo remission. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 771-81	5.8	30
102	The pharmacogenetics of antipsychotic-induced adverse events. <i>Current Opinion in Psychiatry</i> , <b>2013</b> , 26, 144-50	4.9	39
101	KIBRA polymorphism is associated with individual differences in hippocampal subregions: evidence from anatomical segmentation using high-resolution MRI. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 13088-93	6.6	39
100	Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 11-7	1.7	39

99	Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , <b>2013</b> , 28, 183-7	2.3	12
98	The influence of dopamine-related genes on perceptual stability. <i>European Journal of Neuroscience</i> , <b>2013</b> , 38, 3378-83	3.5	15
97	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 272-9	3.5	43
96	Genetics of antipsychotic-induced weight gain: update and current perspectives. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 2067-83	2.6	32
95	Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. <i>Journal of Psychiatric Research</i> , <b>2012</b> , 46, 462-8	5.2	24
94	Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , <b>2012</b> , 12, 156-64	3.5	47
93	Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 38, 134-41	5.5	58
92	Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 904-12		142
91	The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 39, 96-101	5.5	56
90	Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. <i>Molecular Psychiatry</i> , <b>2012</b> , 17, 242-66	15.1	186
89	The AmpliChip <sup>®</sup> CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2012</b> , 16, 897-903	1.6	27
88	Pharmacogenetics of obsessive-compulsive disorders. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 71-81	2.6	29
87	Association between oxytocin receptor gene polymorphisms and self-rated empathic concern in schizophrenia. <i>PLoS ONE</i> , <b>2012</b> , 7, e51882	3.7	59
86	Genetics and personalized medicine in antidepressant treatment. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5853-78	3.3	18
85	Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. <i>Pharmacogenomics Journal</i> , <b>2012</b> , 12, 260-6	3.5	23
84	ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. <i>World Journal of Biological Psychiatry</i> , <b>2011</b> , 12, 392-7	3.8	37
83	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. <i>Schizophrenia Research</i> , <b>2011</b> , 132, 121-4	3.6	20
82	Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2011</b> , 4, 83-93	2.1	23

81	PharmGKB summary: carbamazepine pathway. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 906-10	1.9	64
80	Pharmacogenetics of alcohol, nicotine and drug addiction treatments. <i>Addiction Biology</i> , <b>2011</b> , 16, 357-74.6	4.6	51
79	Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , <b>2011</b> , 13, 198-207	3.8	29
78	Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 277-91	2.6	19
77	Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 386-91	2.3	8
76	Imaging and quantifying chemical and physical properties of native proteins at molecular resolution by force-volume AFM. <i>Angewandte Chemie - International Edition</i> , <b>2011</b> , 50, 12103-8	16.4	80
75	Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders. <i>PLoS ONE</i> , <b>2011</b> , 6, e20982	3.7	53
74	Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 1561-71	2.6	89
73	Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 62-72	2.9	38
72	A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1315-24	8.7	84
71	Neural markers of genetic vulnerability to drug addiction. <i>Current Topics in Behavioral Neurosciences</i> , <b>2010</b> , 3, 277-99	3.4	15
70	Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 773-80	2.6	62
69	The catechol-O-methyl-transferase gene in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , <b>2010</b> , 11, 803-12	3.8	23
68	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. <i>Pharmacogenomics Journal</i> , <b>2010</b> , 10, 200-18	3.5	54
67	Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinone oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 50-6	5.5	48
66	Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 1484-90	5.5	14
65	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 598-604	5.2	22
64	Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. <i>Human Psychopharmacology</i> , <b>2010</b> , 25, 253-9	2.3	27

63	Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1169-76	2.6	40
62	Pharmacogenetics of anxiolytic drugs. <i>Journal of Neural Transmission</i> , <b>2009</b> , 116, 667-77	4.3	32
61	Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 168-74	3.5	27
60	Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia. <i>Schizophrenia Research</i> , <b>2009</b> , 114, 33-8	3.6	12
59	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 317-28	1.2	43
58	The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. <i>Dialogues in Clinical Neuroscience</i> , <b>2009</b> , 11, 363-76	5.7	14
57	Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. <i>Schizophrenia Research</i> , <b>2008</b> , 106, 248-52	3.6	24
56	Serotonin transporter gene and adverse life events in adult ADHD. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2008</b> , 147B, 1461-9	3.5	36
55	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 37-40	3.5	12
54	HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. <i>Human Psychopharmacology</i> , <b>2007</b> , 22, 463-7	2.3	37
53	Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. <i>Molecular Psychiatry</i> , <b>2007</b> , 12, 794-5	15.1	69
52	Genetic research with intermediate phenotypes: phenocopies, perspectives and pitfalls. <i>Addiction</i> , <b>2007</b> , 102, 1696-7	4.6	5
51	Disturbed frontal gyrification within families affected with schizophrenia. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 805-13	5.2	55
50	Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. <i>NeuroMolecular Medicine</i> , <b>2007</b> , 9, 169-77	4.6	45
49	Functional cortical effects of novel allelic variants of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in humans. <i>Pharmacopsychiatry</i> , <b>2007</b> , 40, 191-5	2	7
48	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 639-51	5.8	56
47	Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 697-704	5.8	88
46	Molecular mechanisms of schizophrenia. <i>Cellular Physiology and Biochemistry</i> , <b>2007</b> , 20, 687-702	3.9	214

45	Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. <i>Psychopharmacology</i> , <b>2006</b> , 188, 171-82	4.7	39
44	Gene-gene interaction between MAOA and COMT in suicidal behavior: analysis in schizophrenia. <i>Brain Research</i> , <b>2006</b> , 1097, 26-30	3.7	35
43	Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. <i>Journal of Psychiatric Research</i> , <b>2006</b> , 40, 646-55	5.2	10
42	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. <i>Pharmacogenomics</i> , <b>2006</b> , 7, 863-87	2.6	127
41	Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. <i>Psychiatry Research</i> , <b>2006</b> , 141, 123-8	9.9	25
40	Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. <i>British Journal of Psychiatry</i> , <b>2006</b> , 189, 317-23	5.4	92
39	No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. <i>Psychiatric Genetics</i> , <b>2006</b> , 16, 197-203	2.9	6
38	Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2005</b> , 15, 525-31	1.2	52
37	Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics. <i>European Psychiatry</i> , <b>2005</b> , 20, 65-9	6	19
36	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , <b>2005</b> , 379, 81-9	3.3	82
35	Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , <b>2005</b> , 51, 381-4	10.2	8
34	Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. <i>Psychopharmacology</i> , <b>2005</b> , 181, 179-87	4.7	76
33	Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. <i>Neuropsychopharmacology</i> , <b>2004</b> , 29, 1522-6	8.7	123
32	Etiopathogenetic mechanisms in long-term course of schizophrenia. <i>Pharmacopsychiatry</i> , <b>2004</b> , 37 Suppl 2, S136-40	2	5
31	Analysis of the novel TPH2 gene in bipolar disorder and suicidality. <i>Molecular Psychiatry</i> , <b>2004</b> , 9, 896-7	15.1	50
30	Clinical implications of pharmacogenomics for tardive dyskinesia. <i>Pharmacogenomics Journal</i> , <b>2004</b> , 4, 77-87	3.5	44
29	Pharmacogenetics of antipsychotic-induced weight gain. <i>Pharmacological Research</i> , <b>2004</b> , 49, 309-29	10.2	61
28	CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 73-8	2	32



27	Genetics of schizophrenia: current strategies. <i>Clinical Neuroscience Research</i> , <b>2003</b> , 3, 5-16		6
26	Overview: Towards individualized treatment in schizophrenia. <i>Drug Development Research</i> , <b>2003</b> , 60, 75-94	5.1	8
25	Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. <i>American Journal of Medical Genetics Part A</i> , <b>2003</b> , 119B, 35-9		40
24	Further evidence for age of onset being an indicator for severity in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2002</b> , 68, 343-5	6.6	35
23	Association between a polymorphism in the pseudoautosomal X-linked gene SYBL1 and bipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 74-8		22
22	Association study between two variants in the DOPA decarboxylase gene in bipolar and unipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 519-22		17
21	Different negative priming impairments in schizophrenia and subgroups of obsessive-compulsive disorder. <i>Psychological Medicine</i> , <b>2002</b> , 32, 459-68	6.9	22
20	Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. <i>Pharmacopsychiatry</i> , <b>2002</b> , 35, 157-8	2	36
19	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2001</b> , 251, 193-8	5.1	34
18	No evidence for linkage by transmission disequilibrium test analysis of microsatellite marker D22S278 and schizophrenia in a Palestinian Arab and in a German population. <i>American Journal of Medical Genetics Part A</i> , <b>2001</b> , 105, 328-31		3
17	Caught in the trio trap? Potential selection bias inherent to association studies using parent-offspring trios. <i>American Journal of Medical Genetics Part A</i> , <b>2001</b> , 105, 351-3		20
16	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. <i>American Journal of Medical Genetics Part A</i> , <b>2001</b> , 105, 498-501		47
15	A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25--q26. <i>Molecular Psychiatry</i> , <b>2001</b> , 6, 342-9	15.1	49
14	A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. <i>Human Molecular Genetics</i> , <b>2001</b> , 10, 2933-44	5.6	113
13	Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?. <i>European Psychiatry</i> , <b>2001</b> , 16, 71-4	6	6
12	Familial occurrence of tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , <b>2001</b> , 104, 375-9	6.5	69
11	Investigation of the human serotonin 6 (5-HT6) receptor gene in bipolar affective disorder and schizophrenia <b>2000</b> , 96, 217-221		56
10	Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls. <i>American Journal of Medical Genetics Part A</i> , <b>2000</b> , 96, 310-1		16

9	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. <i>American Journal of Medical Genetics Part A</i> , <b>2000</b> , 96, 801-803		147
8	Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). <i>Molecular Psychiatry</i> , <b>2000</b> , 5, 275-82	15.1	93
7	Dopamine D3 receptor variant and tardive dyskinesia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2000</b> , 250, 31-5	5.1	50
6	Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2000</b> , 59, 544-58	3.1	114
5	Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuroscience Letters</i> , <b>2000</b> , 289, 147-51	3.3	54
4	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder <b>2000</b> , 96, 801		1
3	Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. <i>Lancet, The</i> , <b>1997</b> , 350, 1857-8	4.0	8
2	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI		1
1	Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report		1